Methodology for the Annual China Drug Market Reports

Prelude

Chapter I:       Summary of Hypertension Drugs

Section 1:  R&D History of Hypertension Drugs

Section 2:  Classifications of Hypertension Drugs

2.1 Diuretics

2.2 β-blockers

2.3 Calcium Antagonist

2.4 Angiotensin Converting Enzyme Inhibitor (ACEI)

2.5 Angiotensin II Receptor Antagonist (AIIRA or ARB)

2.6 α1- Blockers

Chapter II:      Global Market of Hypertension Drugs

Chapter III:    The Chinese Market of Hypertension Drugs

Section 1:  The Chinese Hospital Market Sizes of Hypertension Drugs

Section 2:  Chinese Hospital Market Shares of Hypertension Drugs

Section 3:  Chinese Hospital Market Shares of Top 20 Hypertension Drugs

Section 4:  Market Shares of Hypertension Drug Manufacturers

Section 5:  Sales Growth Rates of the Top 20 Hypertension Drugs in the Chinese Hospital Market

Section 6:  Market Shares Analysis of Hypertension Drugs by Category

6.1 Calcium Antagonist

6.1.1 Amlodipine

6.1.2 Nifedipine

6.1.3 Felodipine

6.1.4 Nimodipine

6.1.5 Levamlodipine

6.2 Angiotensin II Receptor Antagonist (AIIRA, or ARB)

6.2.1 Valsartan

6.2.2 Losartan Potassium/Losartan Potassium + hydrochlorothiazide

6.2.3 Irbesartan

6.2.4 Telmisartan

6.3 Angiotensin Converting Enzyme Inhibitor (ACEI)

6.3.1 Benazepril

6.3.2 Fosinopril

6.3.3 Perindopril

6.3.4 Ramipril

6.3.5 Enalapril

6.3.6 Captopril

6.4 β-blockers

6.4.1 Bisoprolol

6.4.2 Metoprolol

6.4.3 Carvedilol

6.4.4 Esmolol

6.4.5 Other Hypertension Drugs 

Chapter IV:     Brand Names, Generic Names, and Manufacturers of Hypertension Drugs

Chapter V:       Packages, Manufacture Quality, Hospital Bidding Prices and Retail Prices of Hypertension Drugs & Hypertension Drugs on the National Healthcare Insurance Coverage List

Chapter VI:     Government Policies for the Hypertension Drug Market

Chapter VII:    R&D of Hypertension Drugs

Section 1:  New Development of Hypertension Drugs

1. Renin-angiotensin System Inhibitor

2. Type T Calcium Channel Block

3. K Channel Inducer

4. Imidazoline Receptor Agonists

5. Endothelin receptor antagonist

6. 5-hydroxy Tryptamine Receptor Inhibitor

7. Neuropeptide Y inhibitor

8. Calcitonin Gene-related Peptide (CGRP)

Section 2:  Clinical Applications of Hypertension Drugs

1. Clinical Evaluation of Hypertension Drugs

2. Interference with Patients of High Normal Blood Pressure

3. Stable Blood Pressure Control

Table 1:     Hypertension Disease of Chinese Residents (‰) 1998 – 2003

Table 2:     Hypertension Drugs Approved by the US FDA between 2000-2002

Table 3:     Hypertension Drugs Approved in 2007

Table 4:     Hypertension Drugs Listed among the Top 50 Best Selling Drugs in 2006

Table 5:     The Top 10 Best Selling Drug Categories 2007

Table 6:     Market Shares of Different Hypertension Drug Categories 2003-2007

Table 7:     Market Shares of the Top 20 Hypertension Drugs 2005-2007

Table 8:     Market Shares of the Top 20 Companies in the Chinese Hypertension Drug Market 2005-2007

Table 9:     Market Growth Rates of the Top 20 Hypertension Drugs 2005-2007

Table 10:   The Top 5 Drugs in Each of the Six Hypertension Drug Categories.

Table 11:   Manufacturers, Market Shares and Sizes of Amlodipine in 2007

Table 12:   Manufacturers, Market Shares and Sizes of Nifedipine 2007

Table 13:   Manufacturers, Market Shares and Sizes of Felodipine 2007

Table 14:   Manufacturers, Market Shares and Sizes of Nimodipine 2007

Table 15:   Manufacturers, Market Shares and Sizes of Levamlodipine 2007

Table 16:   Manufacturers, Market Shares and Sizes of Valsartan 2007

Table 17:   Manufacturers, Market Shares and Sizes of Irbesartan2007

Table 18:   Manufacturers, Market Shares and Sizes of Telmisartan2007

Table 19:   Manufacturers, Market Shares and Sizes of Benazepril 2007

Table 20:   Manufacturers, Market Shares and Sizes of Fosinopril 2007

Table 21:   Manufacturers, Market Shares and Sizes of Ramipril 2007

Table 22:   Manufacturers, Market Shares and Sizes of Enalapril 2007

Table 23:   Manufacturers, Market Shares and Sizes of Captopril 2007

Table 24:   Manufacturers, Market Shares and Sizes of Bisoprolol 2007

Table 25:   Manufacturers, Market Shares and Sizes of Metoprolol 2007

Table 26:   Manufacturers, Market Shares and Sizes of Carvedilol 2007

Table 27:   Manufacturers, Market Shares and Sizes of Esmolol 2007

Table 28:   Brand Names, Chemical Names and Manufacturers of Hypertension Drugs in China

Table 29:   Packages, Quality, Hospital Bidding Prices and Retail Prices of Hypertension Drugs

Table 30:   Hypertension Drugs on National Healthcare Insurance Coverage List

Table 31:   Compelling Indications for Hypertension Drugs as Defined in the JNC7

Table 32:   Preferred Drugs by the 2007 European Hypertension Treatment Guideline

Figure 1:    The Sizes and Growth Rates of the Chinese Hypertensive Drug Market 2003-2007

The Top 20 Pharmaceutical Companies in the Chinese Hypertension Drug Market (with at least >0.86% market shares of the Chinese hypertension drug market)

·         Bayer

·         Pfizer

·         Novartis

·         AstraZeneca

·         MSD

·         sanofi-aventis

·         BMS

·         Beijing Saike

·         Jilin Tianfeng

·         Servier

·         Roche

·         Merck

·         Yangtze River

·         Boehringer-Ingelheim

·         Altana Pharma AG

·         Tanabe

·         Suzhou Dong Rui Jiangsu Suzhou Dongrui

·         Jiangsu Nanjing Xingang

·         Beijing Huasu

·         Shanghai Xianda